proline and nirmatrelvir

proline has been researched along with nirmatrelvir in 36 studies

Research

Studies (36)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	36 (100.00)	2.80

Authors

Authors	Studies
Bassani, D; Bolcato, G; Moro, S; Pavan, M; Sturlese, M	1
Ekanayake, KB; George, J; Jackson, C; Mahawaththa, MC; Morewood, R; Nitsche, C; Otting, G; Sasi, VM; Shuttleworth, L; Ullrich, S; Whitefield, C; Zhang, X	1
Ramos-Guzmán, CA; Ruiz-Pernía, JJ; Tuñón, I	1
Ahmad, B; Ain, QU; Batool, M; Choi, S; Kim, MS	1
Macchiagodena, M; Pagliai, M; Procacci, P	1
Duan, Y; Fang, C; Feng, L; Ma, D; Peng, C; Rao, Z; Shao, M; Wang, H; Yang, H; Yang, K; Yang, X; Zhang, L; Zhang, Q; Zhang, R; Zhao, J; Zhao, X; Zhao, Y; Zhu, Y	1
Karrenbrock, M; Macchiagodena, M; Pagliai, M; Procacci, P	1
Allerton, CMN; Anderson, AS; Aschenbrenner, L; Avery, M; Berritt, S; Boras, B; Cardin, RD; Carlo, A; Coffman, KJ; Dantonio, A; Di, L; Eng, H; Ferre, R; Gajiwala, KS; Gibson, SA; Greasley, SE; Hurst, BL; Kadar, EP; Kalgutkar, AS; Lee, J; Lee, JC; Liu, W; Mason, SW; Noell, S; Novak, JJ; Obach, RS; Ogilvie, K; Owen, DR; Patel, NC; Pettersson, M; Rai, DK; Reese, MR; Sammons, MF; Sathish, JG; Singh, RSP; Steppan, CM; Stewart, AE; Tuttle, JB; Updyke, L; Verhoest, PR; Wei, L; Yang, Q; Zhu, Y	1
Davies, GW; Heskin, J; Jones, R; Moore, LSP; Mughal, N; Pallett, SJC; Rayment, M	1
Drożdżal, S; Ghavami, S; Kotfis, K; Lechowicz, K; Lorzadeh, S; Machaj, F; Przybyciński, J; Rosik, J; Szostak, B; Łos, MJ	1
Fetta, S; Kontoghiorghe, CN; Kontoghiorghes, GJ	1
André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L	1
Bowman, CJ; Campion, SN; Cappon, GD; Catlin, NR; Cheung, JR; Nowland, WS; Sathish, JG; Stethem, CM; Updyke, L	1
Bajaj, SS; Stanford, FC	1
Lee, TC; McDonald, EG	1
Boras, B; Dantonio, AL; Di, L; Eng, H; Kadar, EP; Kalgutkar, AS; Kimoto, E; Lin, J; Novak, JJ; Obach, RS; Patel, NC; Singh, RSP; Walker, GS	1
Abdelnabi, R; Augustijns, P; Chatelain, E; De Jonghe, S; Escudié, F; Foo, CS; Hoglund, RM; Jochmans, D; Mols, R; Mowbray, CE; Neyts, J; Scandale, I; Sjö, P; Tarning, J; Vangeel, L; Wattanakul, T; Weynand, B	1
Abreu, P; Baniecki, M; Bao, W; Damle, B; Gardner, A; Hammond, J; Hendrick, VM; Leister-Tebbe, H; Pypstra, R; Rusnak, JM; Simón-Campos, A; Wisemandle, W	1
Baden, LR; Morrissey, S; Rubin, EJ	1
Ekanayake, KB; Nitsche, C; Otting, G; Ullrich, S	1
Iglesias, C; Reina, J	1
Brown, RS; Chen, JK; Hedvat, J; Jennings, DL; Kovac, DB; Lange, NW; Pereira, MR; Salerno, DM; Scheffert, J; Shertel, T	1
Foerster, KI; Haefeli, WE; Mikus, G; Said, A; Schulz, M; Terstegen, T; Vogt, C	1
Allen, R; Anderson, AS; Bergman, A; Binks, M; Chan, PL; Clark, F; Hackman, F; Kadar, EP; Menon, S; Nucci, G; Pawlak, S; Rao, R; Shi, H; Singh, RSP; Toussi, SS; Van Eyck, L	1
Fan, X; Fu, R; Fu, Y; Jiang, H; Li, J; Lin, C; McCormick, PJ; Yang, Y; Yu, B; Zeng, P; Zhang, J; Zhang, Y; Zhong, F; Zhou, X	1
Costacurta, F; Geley, S; Harris, RS; Heilmann, E; Mogadashi, SA; Rupp, B; Volland, A; von Laer, D	1
Cherrington, NJ; Hau, RK; Wright, SH	1
Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H	1
Alvarado, YJ; González-Paz, L; Hurtado-León, ML; Jeffreys, LN; Loroño, M; Lossada, C; Olivarez, Y; Paz, JL; Torres, FJ; Vera, E; Vera-Villalobos, J; Vivas, A	1
Rubin, R	1
Allen, R; Alugubelli, YR; Blankenship, LR; Cho, CC; Geng, ZZ; Ji, H; Khatua, K; Li, P; Liu, WR; Ma, XR; Ma, Y; Sankaran, B; Shaabani, N; Vatansever, EC; Xiao, J; Xu, S; Yang, KS; Yu, G	1
Bahmanyar, M; Marzi, M; Vakil, MK; Zarenezhad, E	1
Kuehn, BM	1
Arbel, R; Balicer, R; Battat, E; Ben-Shlomo, Y; Dagan, N; Friger, M; Hammerman, A; Hoshen, M; Lavie, G; Netzer, D; Peretz, A; Serby, D; Sergienko, R; Waxman, JG; Wolff Sagy, Y; Yaron, S	1
Chen, TC; Cheng, TL; Huang, BC; Li, CC; Liao, JM; Lin, WW; Wang, YT	1
Bian, Q; Chavez, A; Culbertson, B; Duan, Y; Goff, SP; Ho, DD; Hong, SJ; Iketani, S; Lin, M; Liu, X; Lu, Y; Luck, MI; Mohri, H; Rao, Z; Sabo, Y; Sun, H; Wang, H; Yang, H; Yang, K; Yang, X; Zhang, X; Zhou, H; Zhu, Y	1

Reviews

4 review(s) available for proline and nirmatrelvir

Article	Year
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2021, Volume: 59 Topics: Adult; Antiviral Agents; COVID-19; COVID-19 Serotherapy; Humans; Immunization, Passive; Lactams; Leucine; Nitriles; Pandemics; Pharmaceutical Preparations; Proline; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome	2021
The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic. Frontiers in bioscience (Landmark edition), 2021, 12-30, Volume: 26, Issue:12 Topics: Antiviral Agents; COVID-19; Drug Delivery Systems; Humans; Lactams; Leucine; Nitriles; Pandemics; Proline; SARS-CoV-2	2021
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35, Issue:3 Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Humans; Indoles; Lactams; Leucine; Nitriles; Peptide Hydrolases; Proline; Protease Inhibitors; Pyrrolidinones; Ritonavir; SARS-CoV-2	2022
Paxlovid: Mechanism of Action, Synthesis, and BioMed research international, 2022, Volume: 2022 Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; COVID-19 Vaccines; Cysteine Endopeptidases; Drug Combinations; Humans; Lactams; Leucine; Nitriles; Pandemics; Proline; Protease Inhibitors; Ritonavir; SARS-CoV-2; Viral Nonstructural Proteins	2022

Trials

2 trial(s) available for proline and nirmatrelvir

Article	Year
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England journal of medicine, 2022, 04-14, Volume: 386, Issue:15 Topics: Administration, Oral; Adult; Antiviral Agents; COVID-19 Drug Treatment; Disease Progression; Double-Blind Method; Hospitalization; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Treatment Outcome; Vaccination; Viral Load; Viral Protease Inhibitors	2022
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Clinical pharmacology and therapeutics, 2022, Volume: 112, Issue:1 Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2	2022

Article

Year

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.

The New England journal of medicine, 2022, 04-14, Volume: 386, Issue:15

Topics: Administration, Oral; Adult; Antiviral Agents; COVID-19 Drug Treatment; Disease Progression; Double-Blind Method; Hospitalization; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Treatment Outcome; Vaccination; Viral Load; Viral Protease Inhibitors

2022

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

Clinical pharmacology and therapeutics, 2022, Volume: 112, Issue:1

Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2

2022

Other Studies

30 other study(ies) available for proline and nirmatrelvir

Article	Year
Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. Journal of enzyme inhibition and medicinal chemistry, 2021, Volume: 36, Issue:1 Topics: Antiviral Agents; Humans; Lactams; Leucine; Ligands; Molecular Dynamics Simulation; Nitriles; Peptide Hydrolases; Proline; Protease Inhibitors; SARS-CoV-2; Software	2021
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. Bioorganic & medicinal chemistry letters, 2021, 10-15, Volume: 50 Topics: Coronavirus 3C Proteases; COVID-19; Cysteine; Humans; Lactams; Leucine; Nitriles; Peptides; Peptidomimetics; Proline; Protease Inhibitors; SARS-CoV-2; Structure-Activity Relationship; Substrate Specificity	2021
Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease. Chemical communications (Cambridge, England), 2021, Sep-09, Volume: 57, Issue:72 Topics: Binding Sites; Catalytic Domain; Coronavirus 3C Proteases; COVID-19; Humans; Lactams; Leucine; Molecular Dynamics Simulation; Nitriles; Proline; Protease Inhibitors; Quantum Theory; SARS-CoV-2; Thermodynamics	2021
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International journal of molecular sciences, 2021, Aug-24, Volume: 22, Issue:17 Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Coronavirus Protease Inhibitors; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Proline; Ritonavir; SARS-CoV-2	2021
Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease. Journal of molecular graphics & modelling, 2022, Volume: 110 Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; Humans; Lactams; Leucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Proline; Protease Inhibitors; SARS-CoV-2	2022
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein & cell, 2022, Volume: 13, Issue:9 Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; Humans; Lactams; Leucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Proline; Protease Inhibitors; SARS-CoV-2	2022
Virtual Double-System Single-Box for Absolute Dissociation Free Energy Calculations in GROMACS. Journal of chemical information and modeling, 2021, 11-22, Volume: 61, Issue:11 Topics: Antiviral Agents; COVID-19; Entropy; Lactams; Leucine; Molecular Dynamics Simulation; Nitriles; Proline; SARS-CoV-2	2021
An oral SARS-CoV-2 M Science (New York, N.Y.), 2021, Dec-24, Volume: 374, Issue:6575 Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Coronavirus; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Therapy, Combination; Humans; Lactams; Leucine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitriles; Proline; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Viral Protease Inhibitors; Virus Replication	2021
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. Lancet (London, England), 2022, 01-01, Volume: 399, Issue:10319 Topics: COVID-19 Drug Treatment; Drug Interactions; Drug Therapy, Combination; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; Viral Protease Inhibitors	2022
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral research, 2022, Volume: 198 Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication	2022
Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M Reproductive toxicology (Elmsford, N.Y.), 2022, Volume: 108 Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Embryonic Development; Female; Fertility; Infertility; Lactams; Leucine; Male; Nitriles; Pregnancy; Proline; Rabbits; Rats; Rats, Wistar; Ritonavir	2022
COVID-19: LMICs need antivirals as well as vaccines. Nature, 2022, Volume: 602, Issue:7895 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline	2022
Nirmatrelvir-ritonavir for COVID-19. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2022, 02-14, Volume: 194, Issue:6 Topics: Administration, Oral; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Viral Protease Inhibitors	2022
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Drug metabolism and disposition: the biological fate of chemicals, 2022, Volume: 50, Issue:5 Topics: Administration, Oral; Animals; Child; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Haplorhini; Humans; Lactams; Leucine; Microsomes, Liver; Nitriles; Peptide Hydrolases; Proline; Rats; Ritonavir; SARS-CoV-2	2022
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature communications, 2022, 02-15, Volume: 13, Issue:1 Topics: A549 Cells; Administration, Oral; Animals; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Humans; Lactams; Leucine; Mesocricetus; Nitriles; Proline; Respiratory Mucosa; SARS-CoV-2; Vero Cells; Viral Protease Inhibitors; Virus Replication	2022
Audio Interview: A New Antiviral against Covid-19. The New England journal of medicine, 2022, 02-17, Volume: 386, Issue:7 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Drug Combinations; Drug Interactions; Female; Humans; Immunity, Active; Immunogenicity, Vaccine; Lactams; Leucine; Male; Nitriles; Proline; Research Design; Ritonavir; Vaccine Efficacy; Viral Protease Inhibitors	2022
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorganic & medicinal chemistry letters, 2022, 04-15, Volume: 62 Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Nitriles; Pandemics; Peptide Hydrolases; Proline; Protease Inhibitors; SARS-CoV-2	2022
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022, Volume: 22, Issue:8 Topics: Adult; Calcineurin Inhibitors; COVID-19 Drug Treatment; Cyclosporine; Graft Rejection; Humans; Immunosuppressive Agents; Lactams; Leucine; Nitriles; Organ Transplantation; Proline; Retrospective Studies; Ritonavir; Sirolimus; Tacrolimus; Transplant Recipients	2022
Oral Drugs Against COVID-19. Deutsches Arzteblatt international, 2022, 04-15, Volume: 119, Issue:15 Topics: COVID-19; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Lactams; Leucine; Nitriles; Proline; Ritonavir	2022
Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. Journal of virology, 2022, 04-27, Volume: 96, Issue:8 Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Middle East Respiratory Syndrome Coronavirus; Nitriles; Peptide Hydrolases; Proline; Protease Inhibitors; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2022
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Communications biology, 2022, 04-27, Volume: 5, Issue:1 Topics: COVID-19; Cysteine Endopeptidases; Humans; Indoles; Lactams; Leucine; Nitriles; Peptide Hydrolases; Proline; Protease Inhibitors; Pyrrolidinones; SARS-CoV-2; Viral Proteins	2022
PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. Clinical and translational science, 2022, Volume: 15, Issue:7 Topics: Antiviral Agents; COVID-19 Drug Treatment; Endothelial Cells; Humans; Lactams; Leucine; Nitriles; Proline; SARS-CoV-2; United States	2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, Volume: 607, Issue:7917 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles	2022
Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT. Computational biology and chemistry, 2022, Volume: 99 Topics: Antiviral Agents; COVID-19; Drug Combinations; Humans; Ivermectin; Lactams; Leucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Pandemics; Peptide Hydrolases; Proline; Protease Inhibitors; Ritonavir; SARS-CoV-2; Thermodynamics	2022
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid. JAMA, 2022, 06-28, Volume: 327, Issue:24 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Humans; Lactams; Leucine; Nitriles; Proline; Recurrence; Ritonavir; Viral Protease Inhibitors	2022
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. European journal of medicinal chemistry, 2022, Oct-05, Volume: 240 Topics: Antiviral Agents; Carbamates; Carbutamide; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Nitriles; Proline; Protease Inhibitors; SARS-CoV-2	2022
Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare. JAMA, 2022, 07-26, Volume: 328, Issue:4 Topics: Antiviral Agents; Drug Combinations; Emergency Service, Hospital; Hospitalization; Humans; Lactams; Leucine; Nitriles; Patient Readmission; Proline; Ritonavir	2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Lactams; Leucine; Middle Aged; Nitriles; Proline; SARS-CoV-2; Treatment Outcome	2022
Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. Physical chemistry chemical physics : PCCP, 2022, Sep-28, Volume: 24, Issue:37 Topics: Antiviral Agents; Coronavirus 3C Proteases; Cysteine Endopeptidases; Lactams; Leucine; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Peptide Hydrolases; Proline; SARS-CoV-2	2022
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature, 2023, Volume: 622, Issue:7982 Topics: Antiviral Agents; Binding Sites; Coronavirus 3C Proteases; COVID-19; Drug Design; Drug Resistance, Viral; Humans; Lactams; Leucine; Mutation; Nitriles; Proline; SARS-CoV-2; Substrate Specificity; Virus Replication	2023